Results 61 to 70 of about 50,819 (268)
Interleukin‐39 is a Prognostic Biomarker and Therapy Target for Sepsis
Advanced Science, EarlyView.Sepsis triggers a significant increase in IL‐39 production, with circulating levels markedly elevated and positively correlated with disease severity and poor clinical prognosis in sepsis patients. Mechanistically, macrophage‐derived IL‐39 activates the GP130 signaling pathway via a ligand‐receptor interaction, thereby fueling the pro‐inflammatory ...
Feng‐zhi Zhang +9 more
wiley +1 more source
Concentric Needle Jitter in 97 Myasthenia Gravis Patients
Frontiers in Neurology, 2020 Objectives: To estimate the jitter parameters (single-fiber electromyography) in myasthenia gravis patients mostly by electrical activation in Frontalis, Orbicularis Oculi, and Extensor Digitorum muscles using a concentric needle electrode.Methods ...
João Aris Kouyoumdjian +2 more
doaj +1 more source
Anaesthetic Management of Myasthenia Gravis with Thymic Mass in Facial Trauma [PDF]
, 2010 Myasthenia gravis is an immunologic disorder characterised by polyclonal antibodies directed against nicotinic acetylcholine receptors at postneuromuscular junction.
Dheer Singh, Deepak Sharma
core
Myasthenia Gravis – a new era of treatment options [PDF]
Myasthenia Gravis is an autoimmune disease of the neuromuscular junction that causes fluctuating fatigable neuromuscular weakness. The spectrum of severity ranges from mild intermittent ptosis to respiratory failure requiring ventilatory support ...
Jennifer Spillane, Narmathey Thambirajah
core +1 more source
Clinical predictors for the prognosis of myasthenia gravis
BMC Neurology, 2017 Background Clinical predictors for myasthenia gravis relapse and ocular myasthenia gravis secondary generalization during the first two years after disease onset remain incompletely identified.
Lili Wang, Yun Zhang, Maolin He
doaj +1 more source
Survivin as a potential mediator to support autoreactive cell survival in myasthenia gravis: a human and animal model study. [PDF]
PLoS ONE, 2014 The mechanisms that underlie the development and maintenance of autoimmunity in myasthenia gravis are poorly understood. In this investigation, we evaluate the role of survivin, a member of the inhibitor of apoptosis protein family, in humans and in two ...
Linda L Kusner +4 more
doaj +1 more source
Remission of Myasthenia Gravis: Clinical, Electrophysiological and Immunological Studies [PDF]
, 1993 1993-03The prognosis of 142 patients with myasthenia gravis (MG) was clinically investigated. Forty-nine (35%) had clinical remission (CR) and 23 (16%) good improvement (GI), while 70 (49%) remained in poor condition.
TAKEGAMI, TOSHIHIKO +3 more
core +1 more source
Features of depression development in myasthenia gravis.
Medičnì Perspektivi, 2020 The relative risk of developing depression in myasthenia gravis is 2.14 times higher than in the general population. The features of depression in myasthenia patients remain poorly understood and need to be clarified.
O. I. Kalbus +4 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Cyclizine is a long‐established, short‐acting drug, registered for preventing motion sickness, post‐operative nausea and vomiting (PONV) and ‘vomiting of known cause’. The latter is not defined but may include pregnancy and patients receiving palliative care, historically accepted without large, controlled trials.
Gareth J. Sanger, Paul L. R. Andrews
wiley +1 more source
Head &Neck, EarlyView.ABSTRACT Background Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill‐defined. Hence, known treatment‐related adverse events (TRAEs) and health‐related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care ...
N. D. O'Donnell +11 more
wiley +1 more source